Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 3,158 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Combination Intervention Clear all

Conditions: Lymphoma
Interventions: autologous immunoglobulin idiotype-KLH conjugate vaccine, cyclophosphamide, doxorubicin hydrochloride, prednisone, rituximab, sargramostim, vincristine, Intervention/procedure, antibody therapy, biological therapy, chemotherapy, colony-stimulating factor therapy, cytokine therapy, monoclonal antibody therapy, non-specific immune-modulator therapy, therapeutic procedure, tumor cell derivative vaccine, vaccine therapy; Drug · Procedure
Lead sponsor: Favrille; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Beverly Hills, California • Chapel Hill, North Carolina

Conditions: Type 2 Diabetes Mellitus, Obesity
Interventions: In Person Group (IP), Telephone Conference Call Group (TCC), Medical Nutrition Therapy (MNT); Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 211 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2021
U.S. locations: 4
States / cities: Boston, Massachusetts • Charlestown, Massachusetts • Chelsea, Massachusetts + 1 more

Conditions: Chronic Hepatitis Delta
Interventions: Peginterferon Lambda; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Parkinson' Disease
Interventions: Blood flow restriction (BFR) and aerobic exercise via recumbent stepping (Nu-Step); Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Recurrent Pediatric ALL, Relapsed Pediatric ALL, Acute Lymphoblastic Leukemia, Refractory Pediatric ALL
Interventions: ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, Methotrexate, Cyclophosphamide, 6-thioguanine; Drug
Lead sponsor: Therapeutic Advances in Childhood Leukemia Consortium; Other
Eligibility: Up to 21 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 5
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 2 more

Conditions: Healthy
Interventions: Access to napping/relaxation room, Blue and green light blocking glasses; Behavioral · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 99 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Drug Interaction, Analgesics, Opioid Use Disorder
Interventions: Lemborexant, Placebo, Buprenorphine-naloxone; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Hepatitis C, Chronic, Hepatitis C, Opiate Dependence
Interventions: sofosbuvir/velpatasvir; Drug
Lead sponsor: Community Research Initiative of New England; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Somerville, Massachusetts

Conditions: Skin Cancer Prevention
Interventions: Sunscreen, Text-Message Reminders, Sunscreen and Text Message Reminders, Education; Other · Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 357 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Down Syndrome
Interventions: Combined exercise intervention, Usual care / Sham intervention; Behavioral
Lead sponsor: University of Nevada, Las Vegas; Other
Eligibility: 18 Years to 35 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Vaccine Refusal, Covid19
Interventions: COVID-19 Individual Awareness and Education., COVID-19 Community Outreach & Health Promotion., COVID-19 Individual Health Education & Linkages to Medical and Supportive Services., Pop-up community vaccination sites; Behavioral · Biological
Lead sponsor: Britt Skaathun; Other
Eligibility: 16 Years to 99 Years
Enrollment: 1,051 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 6
States / cities: Chula Vista, California • San Diego, California • San Ysidro, California

Conditions: Acute Kidney Injury
Interventions: Vancomycin, Piperacillin-tazobactam, Cefepime; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV
Interventions: Active Referral, Drop-In Multidisciplinary HIV Care, Mobile HIV Care, Staged Care, Identify and prepare champions at referral sites, Audit and feedback at referral sites, Build a coalition among referral and clinical sites, Assess for readiness and identify barriers, Promote adaptability, Develop a formal implementation blueprint, Develop educational materials; conduct ongoing training, Create a learning collaborative; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 15 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 5
States / cities: Oakland, California • San Francisco, California

Conditions: Lymphoma
Interventions: filgrastim, recombinant human stem cell factor, cyclophosphamide, cytarabine, etoposide, melphalan, mitoxantrone hydrochloride, paclitaxel, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Smoking Cessation
Interventions: NRT, Web Guide, Tweet2Quit; Drug · Behavioral
Lead sponsor: University of California, Irvine; Other
Eligibility: 21 Years to 59 Years
Enrollment: 980 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Irvine, California • Stanford, California

Conditions: Osteoarthritis, Knee, Knee Osteoarthritis, Patellofemoral Osteoarthritis
Interventions: HYMOVIS plus Physical Exercise Program (PEP), Physical Exercise Program (PEP) alone; Device · Other
Lead sponsor: Fidia Pharma USA Inc.; Industry
Eligibility: 21 Years to 60 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 10
States / cities: Tucson, Arizona • Encinitas, California • Los Angeles, California + 5 more

Conditions: Metastatic Microsatellite Stable Colorectal Carcinoma, Refractory Microsatellite Stable Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
Interventions: Abemaciclib, Biopsy Procedure, Biospecimen Collection, Fluorouracil, Radiologic Imaging Procedure; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: Irvine, California • Orange, California • The Bronx, New York + 3 more

Conditions: DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Busulfan, Melphalan, Bortezomib, Autologous Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation; Drug · Procedure
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years to 72 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 4
States / cities: New Brunswick, New Jersey • New York, New York • The Bronx, New York

Conditions: Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Peposertib, Placebo Administration; Procedure · Radiation · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 44
States / cities: Duarte, California • Irvine, California • Orange, California + 35 more

Conditions: Hypertension, Diabetes Mellitis
Interventions: Medical Practice Improvement, Patient Education and Support, Combination Intervention to Include Medical Practice Improvement and Patient Education and Support; Behavioral · Other
Lead sponsor: Harvard Medical School (HMS and HSDM); Other
Eligibility: 18 Years and older
Enrollment: 1,204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Alcoholic Intoxication, Automobile Accident, Cannabis
Interventions: Policy and Training Intervention, Usual and Customary Policy and Training (UC-PT) (Control) Condition; Behavioral
Lead sponsor: Klein Buendel, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Golden, Colorado

Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions: ASP2138, Pembrolizumab, Oxaliplatin, Capecitabine, Folinic acid, 5-FU, Placebo for ASP2138, Placebo for Pembrolizumab; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Saint Louis Park, Minnesota

Conditions: Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia
Interventions: bortezomib, mitoxantrone hydrochloride, etoposide, cytarabine, flow cytometry; Drug · Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Melanoma (Skin)
Interventions: buthionine sulfoximine, melphalan, microarray analysis, high performance liquid chromatography, laboratory biomarker analysis, pharmacological study, biopsy; Drug · Genetic · Other + 1 more
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 2
States / cities: Durham, North Carolina • Houston, Texas

Search by objective public record fields.

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

REAL HEALTH-Diabetes: Reach Ahead for Lifestyle and Health-Diabetes

Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis

Blood Flow Restriction and Exercise in Parkinson's Disease

ABT-751 With Chemotherapy for Relapsed Pediatric ALL

Improving Night Shift Nurses' Health and Reducing Burnout

Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder

A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic

A Randomized Control Trial of Sun Protection Interventions for Operating Engineers

Blood Flow Regulation in Individuals With Down Syndrome - Training Study

Project 2VIDA! COVID-19 Vaccine Intervention Delivery for Adults in Southern California

A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients

Multidisciplinary Low-Barrier and Mobile HIV Care to Improve Retention and Viral Suppression: Stakeholder-Engaged Design and Evaluation

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Twitter-enabled Mobile Messaging for Smoking Relapse Prevention (Tweet2Quit)

2 Weekly Intra-articular Hyaluronan Knee Injections, Given 1 wk. Apart, of HYMOVIS Combined With Physical Exercise Program (PEP) Compared to PEP Alone, in Relatively Young, Active Population of Subjects With Patellofemoral Osteoarthritis (PFOA) and/or Tibiofemoral Osteoarthritis (TFOA)

Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer

Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

Community Partnership to Examine Racial and Ethnic Differences in Health Care for Hypertension and Diabetes

Responsible Marijuana Sales Practices to Reduce the Risk of Selling to Intoxicated Customers

A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer

Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia

A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma